Firma TME Pharma, Autor bei Presse-Blog

TME Pharma reports on end of six-month lock-up period of shares and convertible bonds following the April 2023 transaction

18. Oktober 202321. Oktober 2023 Firma TME PharmaFinanzen / Bilanzena12, brain, cancer, clinical, glioblastoma, gloria, market, nox, optimus, patients, radiotherapy, statements, treatment, tumor, with

TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today the end of the six-month soft lock-up period of shares and the end of Mehr

Results of the 2023 Annual General Meeting of shareholders and resumption of the liquidity contract

3. Juli 2023 Firma TME PharmaFinanzen / Bilanzena12, agm, AMF, brain, cancer, clinical, glioblastoma, market, nox, optimus, patients, radiotherapy, securities, statements, with

TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today the results of its 2023 annual general meeting of shareholders (AGM), which took place Mehr

TME Pharma Announces Positive 15-month Survival Data From GLORIA Expansion Arm Evaluating NOX-A12 in Combination With Radiotherapy and Bevacizumab in Glioblastoma

28. Juni 2023 Firma TME PharmaAllgemeina12, brain, cancer, clinical, glioblastoma, market, methylation, nox, optimus, patients, radiotherapy, statements, strong, vegf, with

83% of glioblastoma patients remain alive after 15 months on study, unchanged from the 14-month survival update 15-month mark further surpasses the expected survival in patients resistant to chemotherapy with incomplete surgical tumor removal Survival data will improve further as Mehr

TME Pharma Announces Convocation of the 2023 Annual General Meeting of Shareholders

30. Mai 2023 Firma TME PharmaAllgemeina12, agm, brain, cancer, clinical, euroclear, glioblastoma, nox, optimus, patients, radiotherapy, report, statements, treatment, with

TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that the annual general meeting of shareholders (the AGM) of the company is convened Mehr

TME Pharma publishes audited annual report 2022

25. April 2023 Firma TME PharmaAllgemeina12, brain, cancer, clinical, fiscal, glioblastoma, market, nox, optimus, patients, radiotherapy, report, statements, supervisory, with

Financial visibility extended into December 2023 Exceptional clinical results generated in brain cancer trial evaluating NOX-A12 in combination with radiotherapy and bevacizumab Survival data continue to improve with 83% of patients alive after one year 15-month Mehr

TME Pharma Announces Successful €2 Million Financing and the End of the Convertible Bond Program with a Lock-Up of New Shares and Lock-Up of Bond Conversions Extending Financial Runway into December 2023

19. April 202320. April 2023 Firma TME PharmaAllgemeina12, aso, atlas, brain, cancer, clinical, glioblastoma, market, new, nox, optimus, patients, radiotherapy, statements, with

€2 million new cash secured Termination of the convertible bond agreement by TME Pharma Lock-up of all new shares issued and all outstanding convertible bonds for a period of 6 months to align investors and support company through next clinical Mehr

TME Pharma Publishes Unaudited Financial Results for Fiscal Year 2022

19. April 202320. April 2023 Firma TME PharmaAllgemeina12, aso, atlas, brain, cancer, clinical, derivatives, fiscal, nox, optimus, patients, radiotherapy, revenues, statements, with

TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces the publication of unaudited financial results for the fiscal year 2022 in order to Mehr

TME Pharma announces convocation of an extraordinary general meeting of shareholders

2. Januar 2023 Firma TME PharmaAllgemeina12, brain, cancer, clinical, egm, euroclear, glioblastoma, nox, optimus, patients, radiotherapy, statements, treatment, tumor, with

TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that an extraordinary general meeting of shareholders (the EGM) of the company is Mehr

TME Pharma announces the resignation of its chief financial officer Bryan Jennings

29. November 2022 Firma TME PharmaFirmeninterna12, brain, cancer, clinical, glioblastoma, market, new, nox, optimus, patients, radiotherapy, statements, treatment, tumor, with

TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that the company’s Chief Financial Officer (CFO), Bryan Jennings, has resigned for personal Mehr

TME Pharma reports H1 2022 Financial results and provides business update

27. Oktober 2022 Firma TME PharmaAllgemeina12, brain, cancer, clinical, drugs, new, nox, optimus, patients, radiotherapy, statements, therapy, treatment, vegf, with

Promising top-line results warrant focus of the clinical development on NOX-A12 combination therapies in brain cancer NOX-A12 + bevacizumab 12-month survival data in glioblastoma expected in April 2023 Cash runway into June 2023 TME Pharma N.V. (Euronext Growth Paris: ALTME), Mehr

Autor: Firma TME Pharma